Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit

Journal of Critical Care

Volumn 27, Issue 6, 2012, Pages 739.e7-739.e13

  Huynh, Thanh N ^a   Weigt, S Sam ^a   Sugar, Catherine A ^a,b   Shapiro, Shelley ^c   Kleerup, Eric C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Intensive care unit; Pulmonary artery catheterization; Pulmonary hypertension

Indexed keywords

AMIODARONE; ATROPINE; DIGOXIN; DOPAMINE; PROSTACYCLIN; SOTALOL;

ABLATION THERAPY; ADULT; APACHE; ARTERIAL PRESSURE; ARTICLE; ARTIFICIAL VENTILATION; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTROLLED STUDY; DIALYSIS; FAINTNESS; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART CATHETERIZATION; HEART INDEX; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OXYGENATION; PROGNOSIS; PULMONARY ARTERY CATHETER; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESUSCITATION; RETROSPECTIVE STUDY; RISK REDUCTION; SINUS RHYTHM; TERTIARY HEALTH CARE; WORLD HEALTH ORGANIZATION;

EID: 84870686875     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.08.006     Document Type: Article

References (23)

1. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004, 351:1655-1665.
2. Chin K.M., Kim N.H., Rubin L.J. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005, 16:13-18.
3. Oudiz R.J., Schilz R.J., Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126:420-427.
4. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
5. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
6. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
7. Wax D., Garofano R., Barst R.J. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999, 116:914-920.
8. Campo A., Mathai S.C., Le Pavec J., et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011, 38:359-367.
9. Hoeper M.M., Galie N., Murali S., et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002, 165:341-344.
10. Zamanian R.T., Haddad F., Doyle R.L., Weinacker A.B. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007, 35:2037-2050.
11. Sztrymf B., Souza R., Bertoletti L., et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010, 35:1286-1293.
12. Benedict N., Seybert A., Mathier M.A. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007, 29:2134-2153.
13. Zimmerman J.E., Kramer A.A., McNair D.S., Malila F.M. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006, 34:1297-1310.
14. Haddad F., Fuh E., Peterson T., et al. Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail 2011, 17:533-539.
15. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997, 30:343-349.
16. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005, 128:2393-2399.
17. Corte T.J., Wort S.J., Gatzoulis M.A., Macdonald P., Hansell D.M., Wells A.U. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax 2009, 64:883-888.
18. Haddad F., Peterson T., Fuh E., et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail 2011, 4:692-699.
19. Richard C., Warszawski J., Anguel N., et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003, 290:2713-2720.
20. Shah M.R., Hasselblad V., Stevenson L.W., et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA 2005, 294:1664-1670.
21. Klings E.S., Farber H.W. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 350:2521-2522. [author reply -2].
22. Hoeper M.M., Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med 2011, 184:1114-1124.
23. Leuchte H.H., Holzapfel M., Baumgartner R.A., Neurohr C., Vogeser M., Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005, 128:2368-2374.